Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy
Advanced Science · 2026
DOI: 10.1002/advs.75406 ↗At a glance
Journal article in Advanced Science, 2026. Written by Jilong Wang and 10 co-authors. Institution: Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, C…. Major MEDLINE topics: Macrophages, Immunotherapy, Oncolytic Viruses, Neoplasms. Cited 3 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Zhejiang Province Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, Zhejiang Provincial Department of Science and Technology.
Abstract (original language)
Macrophage‐based immunotherapy holds great promise for solid tumors but is limited by impaired phagocytosis and unstable M1‐type polarization due to immunosuppressive tumor microenvironments. Here, we develop engineered macrophages by conjugating oncolytic adenovirus (OA)‐loaded zeolitic imidazolate framework‐8 (ZIF‐8) onto macrophage surfaces via bioorthogonal chemistry (ZIFOA‐M). This platform leverages localized viral delivery to selectively downregulate “don't eat me” signals (CD47 and CD24) on tumor cells, thereby restoring macrophage phagocytic capacity. Moreover, viral replication within tumors induces immunogenic cell death, releasing major damage‐associated molecular patterns (DAMPs) that sustain M1‐type polarization and promote durable antitumor immunity. ZIFOA‐M also enhances tumor antigen presentation, eliciting robust tumor‐specific T cell responses. Our strategy integrates phagocytosis restoration, microenvironment remodeling, and adaptive immune activation in a single, localized platform. ZIFOA‐M offers a complementary and translatable approach to overcome key barriers in macrophage‐based cancer immunotherapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Joint Centre of Translational Medicine, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, China.
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain, Health), Wenzhou, Zhejiang, China.
- Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Funding
- National Natural Science Foundation of China
- Zhejiang Province Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation
- Zhejiang Provincial Department of Science and Technology
- Wenzhou High Level Innovation Team Program
- Scientific Research Project of Wenzhou Medical University
- Huadong Medicine Joint Fund of Zhejiang Provincial Natural Science Foundation of China
- Discipline Cluster of Oncology of Wenzhou Medical University in China
Cite
APA
Wang, J., Lu, N., Yan, Z., Ye, L., Bai, L., Yuan, S., Zhu, Y., Xiong, Y., Bai, Y., Chen, Y., & Deng, J. (2026). Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.75406
Vancouver
Wang J, Lu N, Yan Z, Ye L, Bai L, Yuan S, et al. Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy. Advanced Science. 2026. doi:10.1002/advs.75406
BibTeX
@article{Wang2026,
author = {Wang, Jilong and Lu, Ning and Yan, Zhuo and Ye, Luyi and Bai, Luyao and Yuan, Shanshan and Zhu, Yuting and Xiong, Yiru and Bai, Yongheng and Chen, Yaping and Deng, Junjie},
title = {Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.75406}
}
EUVIMED